Leica Biosystems to Expand Pathology Portfolio Through StatLab Acquisition

The agreement will add StatLab, a leading global developer and manufacturer of anatomical pathology products, to Leica Biosystems upon closing.

For more than 50 years, StatLab has supplied anatomic pathology laboratories with products covering pre‑analytical and analytical histology steps, including specimen collection, tissue processing, slide preparation, and staining. The portfolio is designed to help laboratories improve efficiency, standardization, and diagnostic quality. StatLab’s reputation for quality, innovation, and customer partnership aligns with Leica Biosystems’ focus on advancing cancer diagnostics.

The transaction is anticipated to close by the end of 2026 and is subject to customary conditions, including receipt of applicable regulatory clearances. Financial terms were not disclosed. Following the closing, StatLab will become part of Leica Biosystems.

“We are excited by the opportunity to combine StatLab's trusted portfolio with Leica Biosystems' global leadership in pathology, computational pathology and AI-enabled diagnostics. Together, we can solve some of the hardest problems in healthcare by helping laboratories achieve the consistency, standardization, and quality required to adopt AI-enabled cancer diagnostics at scale,” said Gustavo Perez Fernandez, Group Executive, Danaher's Diagnostics business, and President, Leica Biosystems.

“We look forward to welcoming this talented team to Leica Biosystems. Every step we take to accelerate critical cancer diagnostics helps patients get on the path to treatment faster,” added Perez Fernandez.